Margherita Zen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margherita Zen has a total of 372 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Doria
Rheumatology Unit, Department of Medicine, University of Padova , Padova
29 shared publications - Mariele Gatto
Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Italy
11 shared publications - Alessandro Giollo
Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy
9 shared publications Luca Iaccarino
Department of Medicine, Rheumatology Unit, University of Padua, Padua, Veneto, Italy
7 shared publicationsAntonia Calligaro
Rheumatology Unit, Padua University Hospital , Padua
6 shared publicationsGinevra De Marchi
Department of Medicine, University of Udine, Udine, Friuli-Venezia Giulia, Italy
5 shared publications
Latest Publications
- Open Access
Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials
Objective: To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in systemic lupus erythematosus (SLE) using modified definitions that excluded the glucocorticoid (GC) component (‘non-GC-DORIS’ and ‘non-GC-LLDAS’) as the trials lacked mandated GC tapering protocols. Methods: In this post hoc analysis, data of adults with SLE receiving belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo plus standard therapy were pooled from five clinical trials (BLISS-76 ( NCT00410384 ), BLISS-52 ( NCT00424476 ), North East Asia ( NCT01345253 ), BLISS-SC ( NCT01484496 ) and EMBRACE ( NCT01632241 )). Non-GC-DORIS and non-GC-LLDAS attainment rates (calculated based on SLE Disease Activity Index 2000 and Physician’s Global Assessment only) with belimumab versus placebo were compared up to week 52 in the overall population and in patient subgroups of interest. Results: Non-GC-DORIS and non-GC-LLDAS attainment at week 52 were significantly higher with belimumab (n=1869) versus placebo (n=1217; non-GC-DORIS: 18% vs 13%, risk ratio, RR (95% CI): 1.44 (1.20 to 1.71); p<0.001; non-GC-LLDAS: 32% vs 21%, RR (95% CI): 1.50 (1.32 to 1.71); p<0.001). Similar results were observed across most analysed patient subgroups; at week 52, differences were generally greater in the high versus low disease activity subgroups and Asian and White subgroups exhibited significantly higher attainment with belimumab versus placebo. Conclusion: Belimumab was associated with higher attainment of DORIS remission and LLDAS excluding the GC component versus placebo; attainment rates were approximately twofold higher than those previously reported using the full definitions.
Open AccessBelimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials
Objective: To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in systemic lupus erythematosus (SLE) using modified definitions that excluded the glucocorticoid (GC) component (‘non-GC-DORIS’ and ‘non-GC-LLDAS’) as the trials lacked mandated GC tapering protocols. Methods: In this post hoc analysis, data of adults with SLE receiving belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo plus standard therapy were pooled from five clinical trials (BLISS-76 ( NCT00410384 ), BLISS-52 ( NCT00424476 ), North East Asia ( NCT01345253 ), BLISS-SC ( NCT01484496 ) and EMBRACE ( NCT01632241 )). Non-GC-DORIS and non-GC-LLDAS attainment rates (calculated based on SLE Disease Activity Index 2000 and Physician’s Global Assessment only) with belimumab versus placebo were compared up to week 52 in the overall population and in patient subgroups of interest. Results: Non-GC-DORIS and non-GC-LLDAS attainment at week 52 were significantly higher with belimumab (n=1869) versus placebo (n=1217; non-GC-DORIS: 18% vs 13%, risk ratio, RR (95% CI): 1.44 (1.20 to 1.71); p<0.001; non-GC-LLDAS: 32% vs 21%, RR (95% CI): 1.50 (1.32 to 1.71); p<0.001). Similar results were observed across most analysed patient subgroups; at week 52, differences were generally greater in the high versus low disease activity subgroups and Asian and White subgroups exhibited significantly higher attainment with belimumab versus placebo. Conclusion: Belimumab was associated with higher attainment of DORIS remission and LLDAS excluding the GC component versus placebo; attainment rates were approximately twofold higher than those previously reported using the full definitions.
- Open Access
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002269
Impact of pregnancy on organ damage in systemic lupus erythematosus: a multicentre study
Objectives Pregnancy in SLE is associated with increased maternal and fetal risks but its impact on irreversible organ damage remains unclear. We assessed whether pregnancy independently contributes to short-term organ damage accrual in women with SLE.Methods We retrospectively analysed prospectively collected data from two tertiary referral centres with dedicated pregnancy clinics. Women fulfilling SLE classification criteria were included if complete damage assessments were available from 2 years before conception to 1 year after conception. Organ damage was assessed using the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Within-patient SDI changes during the pregnancy/early postpartum period were compared with the pre-pregnancy reference period. Given the limited number of events, effect sizes and CIs were prioritised. Sensitivity analyses included non-parametric effect sizes and restriction to one pregnancy per woman.Results 165 pregnancies were included. At conception, most women were in remission or low disease activity. During pregnancy, 20.6% experienced disease flares, predominantly mild to moderate. Overall, cumulative damage remained stable: mean SDI increased from 0.18±0.43 one year before conception to 0.22±0.52 one year after conception (mean ΔSDI 0.04±0.21), with a median change of zero. Only seven pregnancies (4.2%; 95% CI 2.1% to 8.5%) showed new damage, limited to a single SDI item. Pre-existing damage was associated with progression (OR 6.77; 95% CI 1.43 to 32.05), and the frequency of progression was similar when the analyses were restricted to a single pregnancy per woman (6/126, 4.8%). By contrast, disease activity at the time of conception, flare-ups, obstetric complications and treatments were inconclusive. In the sensitivity analysis, the association with pre-existing damage was confirmed, and baseline disease activity also emerged as associated with damage progression (rank-biserial r=−0.55; 95% CI −0.78 to −0.27, p=0.030).Conclusions In women with predominantly well-controlled SLE, short-term organ damage accrual during pregnancy and the early postpartum period was uncommon. Pre-existing damage was associated with further accrual, while baseline disease activity also emerged as associated in the sensitivity analysis; however, the small number of events limits conclusions regarding other potential risk factors.
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002269
Open AccessImpact of pregnancy on organ damage in systemic lupus erythematosus: a multicentre study
Objectives Pregnancy in SLE is associated with increased maternal and fetal risks but its impact on irreversible organ damage remains unclear. We assessed whether pregnancy independently contributes to short-term organ damage accrual in women with SLE.Methods We retrospectively analysed prospectively collected data from two tertiary referral centres with dedicated pregnancy clinics. Women fulfilling SLE classification criteria were included if complete damage assessments were available from 2 years before conception to 1 year after conception. Organ damage was assessed using the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Within-patient SDI changes during the pregnancy/early postpartum period were compared with the pre-pregnancy reference period. Given the limited number of events, effect sizes and CIs were prioritised. Sensitivity analyses included non-parametric effect sizes and restriction to one pregnancy per woman.Results 165 pregnancies were included. At conception, most women were in remission or low disease activity. During pregnancy, 20.6% experienced disease flares, predominantly mild to moderate. Overall, cumulative damage remained stable: mean SDI increased from 0.18±0.43 one year before conception to 0.22±0.52 one year after conception (mean ΔSDI 0.04±0.21), with a median change of zero. Only seven pregnancies (4.2%; 95% CI 2.1% to 8.5%) showed new damage, limited to a single SDI item. Pre-existing damage was associated with progression (OR 6.77; 95% CI 1.43 to 32.05), and the frequency of progression was similar when the analyses were restricted to a single pregnancy per woman (6/126, 4.8%). By contrast, disease activity at the time of conception, flare-ups, obstetric complications and treatments were inconclusive. In the sensitivity analysis, the association with pre-existing damage was confirmed, and baseline disease activity also emerged as associated with damage progression (rank-biserial r=−0.55; 95% CI −0.78 to −0.27, p=0.030).Conclusions In women with predominantly well-controlled SLE, short-term organ damage accrual during pregnancy and the early postpartum period was uncommon. Pre-existing damage was associated with further accrual, while baseline disease activity also emerged as associated in the sensitivity analysis; however, the small number of events limits conclusions regarding other potential risk factors.
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001934
Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort
Objective: To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Methods: The BeRLiSS (Belimumab in Real Life Setting Study) 2.0 cohort included patients with SLE from 14 Italian referral centres treated with BEL for active joint or skin involvement, based on physician judgement, between June 2013 and May 2024. Clinical and laboratory parameters were recorded at baseline and every 6 months. Patients were eligible if they had baseline haematological abnormalities defined according to British Isles Lupus Assessment Group (BILAG) (grade C or higher): haemoglobin (Hb) ≤10.9 g/dL, platelets (Plts) ≤149×10 9 /L, lymphocytes (Lym) ≤1.0×10 9 /L or leucocytes (Leuc) ≤3.0×10 9 /L. Follow-up data up to month 48 were available for 33 patients with anaemia, 20 with thrombocytopenia, 44 with lymphopenia and 18 with leucopenia. Results: At baseline, 76 patients had anaemia, 44 thrombocytopenia, 107 lymphopenia and 53 leucopenia. Hb levels increased significantly from 9.9±0.6 g/dL to 11.7±1.4 g/dL at month 48 (p9 /L to 176.6±88.7×10 9 /L (p=0.004), Lym counts from 0.72±0.21×10 9 /L to 1.14±0.45×10 9 /L (p9 /L to 4.732±1.897×10 9 /L at 48 months (p<0.001). Improvement in Hb (p=0.97), Plts (p=0.12), Lym (p=0.86) and Leuc (p=0.73) was similar regardless of the use of concomitant immunosuppressants. Glucocorticoid (GC) doses decreased significantly across all manifestations, except for leucopenia: anaemia (12.9±12.1 to 3.6±4.9 mg/day, p=0.003), thrombocytopenia (10.8±9.6 to 4.4±5.5 mg/day, p=0.004), lymphopenia (10.6±8.6 to 3.1±3.2 mg/day, p<0.001). Proportion of GC users declined over 48 months: anaemia 96.1–60.7%, thrombocytopenia 93.1–80%, lymphopenia 96.3–70.3% and leucopenia 95.3–80%. Conclusion: In this real-world cohort, BEL treatment was associated with improvement in anaemia, thrombocytopenia, lymphopenia and leucopenia with over half of patients achieving normalisation of blood counts. Haematological responses were similar regardless of concomitant immunosuppressive therapy, supporting the role of BEL as a therapeutic option for haematological abnormalities in SLE.
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001934
Open AccessEfficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort
Objective: To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Methods: The BeRLiSS (Belimumab in Real Life Setting Study) 2.0 cohort included patients with SLE from 14 Italian referral centres treated with BEL for active joint or skin involvement, based on physician judgement, between June 2013 and May 2024. Clinical and laboratory parameters were recorded at baseline and every 6 months. Patients were eligible if they had baseline haematological abnormalities defined according to British Isles Lupus Assessment Group (BILAG) (grade C or higher): haemoglobin (Hb) ≤10.9 g/dL, platelets (Plts) ≤149×10 9 /L, lymphocytes (Lym) ≤1.0×10 9 /L or leucocytes (Leuc) ≤3.0×10 9 /L. Follow-up data up to month 48 were available for 33 patients with anaemia, 20 with thrombocytopenia, 44 with lymphopenia and 18 with leucopenia. Results: At baseline, 76 patients had anaemia, 44 thrombocytopenia, 107 lymphopenia and 53 leucopenia. Hb levels increased significantly from 9.9±0.6 g/dL to 11.7±1.4 g/dL at month 48 (p9 /L to 176.6±88.7×10 9 /L (p=0.004), Lym counts from 0.72±0.21×10 9 /L to 1.14±0.45×10 9 /L (p9 /L to 4.732±1.897×10 9 /L at 48 months (p<0.001). Improvement in Hb (p=0.97), Plts (p=0.12), Lym (p=0.86) and Leuc (p=0.73) was similar regardless of the use of concomitant immunosuppressants. Glucocorticoid (GC) doses decreased significantly across all manifestations, except for leucopenia: anaemia (12.9±12.1 to 3.6±4.9 mg/day, p=0.003), thrombocytopenia (10.8±9.6 to 4.4±5.5 mg/day, p=0.004), lymphopenia (10.6±8.6 to 3.1±3.2 mg/day, p<0.001). Proportion of GC users declined over 48 months: anaemia 96.1–60.7%, thrombocytopenia 93.1–80%, lymphopenia 96.3–70.3% and leucopenia 95.3–80%. Conclusion: In this real-world cohort, BEL treatment was associated with improvement in anaemia, thrombocytopenia, lymphopenia and leucopenia with over half of patients achieving normalisation of blood counts. Haematological responses were similar regardless of concomitant immunosuppressive therapy, supporting the role of BEL as a therapeutic option for haematological abnormalities in SLE.
- Open Access
Prevalence, incidence, mortality and causes of death in a large cohort of patients with rheumatoid arthritis: an Italian population-based study
Objective: Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and primarily affects the joints. While therapeutic advances have substantially reduced the risk of long-term disability, concerns remain regarding disease-related morbidity. Therefore, we aimed to evaluate incidence, prevalence, mortality rates (MRs), standardised mortality ratios (SMRs) and causes of death in RA in north-eastern Italy from 2012 to 2020. Methods: A retrospective population-based study was conducted in the Veneto region (4.8 million residents) using linked data from the population registry, healthcare co-payment exemptions, hospital discharge records and mortality data. Prevalence and incidence rates were stratified by age and sex. SMRs were calculated by comparing patients with RA to the general population. Causes of death were classified by the International Classification of Diseases Tenth Revision (ICD-10). Results: We identified 37 996 patients with RA (prevalence 0.54%) and 12 875 incident cases (incidence rate 33.1/100 000). Incidence was twice as high in females. Among prevalent cases, 7 435 deaths occurred (MR 32.2/1000), while among incident cases there were 1288 deaths over the 8-year study period (MR 21.3/1000). The median age at death was 83 (77–88) years. The overall SMR was 1.28 (95% CI 1.21 to 1.35), higher in patients under 45 years of age (2.15, 95% CI 0.93 to 4.24). Leading causes of death were cardiovascular diseases (37.1%), cancer (20.6%) and infections (10.9%). Conclusions: This study provides updated data on epidemiology and mortality of RA in Italy, offering insights for healthcare planning and resource allocation. The analysis of causes of death provides additional perspectives for a multidimensional approach to disease management.
Open AccessPrevalence, incidence, mortality and causes of death in a large cohort of patients with rheumatoid arthritis: an Italian population-based study
Objective: Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and primarily affects the joints. While therapeutic advances have substantially reduced the risk of long-term disability, concerns remain regarding disease-related morbidity. Therefore, we aimed to evaluate incidence, prevalence, mortality rates (MRs), standardised mortality ratios (SMRs) and causes of death in RA in north-eastern Italy from 2012 to 2020. Methods: A retrospective population-based study was conducted in the Veneto region (4.8 million residents) using linked data from the population registry, healthcare co-payment exemptions, hospital discharge records and mortality data. Prevalence and incidence rates were stratified by age and sex. SMRs were calculated by comparing patients with RA to the general population. Causes of death were classified by the International Classification of Diseases Tenth Revision (ICD-10). Results: We identified 37 996 patients with RA (prevalence 0.54%) and 12 875 incident cases (incidence rate 33.1/100 000). Incidence was twice as high in females. Among prevalent cases, 7 435 deaths occurred (MR 32.2/1000), while among incident cases there were 1288 deaths over the 8-year study period (MR 21.3/1000). The median age at death was 83 (77–88) years. The overall SMR was 1.28 (95% CI 1.21 to 1.35), higher in patients under 45 years of age (2.15, 95% CI 0.93 to 4.24). Leading causes of death were cardiovascular diseases (37.1%), cancer (20.6%) and infections (10.9%). Conclusions: This study provides updated data on epidemiology and mortality of RA in Italy, offering insights for healthcare planning and resource allocation. The analysis of causes of death provides additional perspectives for a multidimensional approach to disease management.
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001904
Fracture risk tools performance and potential use in systemic lupus erythematosus
Objective: Skeletal fragility is a major comorbidity in systemic lupus erythematosus (SLE), yet the accuracy of fracture risk algorithms in this population remains uncertain. We compared the discriminative ability of Fracture Risk Assessment Tool (FRAX) and the Italian FRAX-derived tool (DeFRA) for fractures in SLE. Methods: This is a secondary analysis of the multicentre osteoporosis and FRagility fracture Among SLE patients (FRAIL - NCT05590390 ) cohort that included patients with SLE who underwent dual-energy X-ray absorptiometry with vertebral fracture assessment (VFA). Vertebral fractures were confirmed by radiography. For each patient, 10-year major osteoporotic fracture probability was calculated using FRAX and DeFRA. Discrimination was assessed with receiver operating characteristic curves and DeLong’s test. Operational thresholds (FRAX ≥20%, DeFRA ≥20% and 15%) were evaluated for sensitivity, specificity, predictive values and number needed to scan (NNS=1/positive predictive value). Robustness of estimates was tested using 2000 bootstrap resamples with out-of-bag evaluation. Results: 106 patients with SLE were included in the study. Mean age was 53.6 years, 88.7% were female and 41.5% were on glucocorticoids. Morphometric vertebral fractures were identified in 23 patients (21.7%), including 15 previously unrecognised. For newly detected fractures, area under the curve (AUC) was higher for DeFRA (0.834, 95% CI 0.725 to 0.944) than FRAX (0.681, 95% CI 0.495 to 0.867; p=0.022). Similar results were observed when considering any vertebral fracture (AUC 0.902 vs 0.770; p=0.013). At operational thresholds, DeFRA ≥20% identified 9/15 new fractures (NNS=1.78) versus 7 with FRAX ≥20%, while lowering the cut-off to DeFRA ≥15% increased sensitivity (10/15 fractures, NNS=2.0) without loss of specificity. Bootstrap validation confirmed the robustness of rank ordering. Conclusion: In SLE, DeFRA outperforms FRAX in detecting vertebral fractures and offers a clinically efficient threshold for guiding targeted VFA, with potential implications for optimising imaging strategies and glucocorticoid management.
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001904
Open AccessFracture risk tools performance and potential use in systemic lupus erythematosus
Objective: Skeletal fragility is a major comorbidity in systemic lupus erythematosus (SLE), yet the accuracy of fracture risk algorithms in this population remains uncertain. We compared the discriminative ability of Fracture Risk Assessment Tool (FRAX) and the Italian FRAX-derived tool (DeFRA) for fractures in SLE. Methods: This is a secondary analysis of the multicentre osteoporosis and FRagility fracture Among SLE patients (FRAIL - NCT05590390 ) cohort that included patients with SLE who underwent dual-energy X-ray absorptiometry with vertebral fracture assessment (VFA). Vertebral fractures were confirmed by radiography. For each patient, 10-year major osteoporotic fracture probability was calculated using FRAX and DeFRA. Discrimination was assessed with receiver operating characteristic curves and DeLong’s test. Operational thresholds (FRAX ≥20%, DeFRA ≥20% and 15%) were evaluated for sensitivity, specificity, predictive values and number needed to scan (NNS=1/positive predictive value). Robustness of estimates was tested using 2000 bootstrap resamples with out-of-bag evaluation. Results: 106 patients with SLE were included in the study. Mean age was 53.6 years, 88.7% were female and 41.5% were on glucocorticoids. Morphometric vertebral fractures were identified in 23 patients (21.7%), including 15 previously unrecognised. For newly detected fractures, area under the curve (AUC) was higher for DeFRA (0.834, 95% CI 0.725 to 0.944) than FRAX (0.681, 95% CI 0.495 to 0.867; p=0.022). Similar results were observed when considering any vertebral fracture (AUC 0.902 vs 0.770; p=0.013). At operational thresholds, DeFRA ≥20% identified 9/15 new fractures (NNS=1.78) versus 7 with FRAX ≥20%, while lowering the cut-off to DeFRA ≥15% increased sensitivity (10/15 fractures, NNS=2.0) without loss of specificity. Bootstrap validation confirmed the robustness of rank ordering. Conclusion: In SLE, DeFRA outperforms FRAX in detecting vertebral fractures and offers a clinically efficient threshold for guiding targeted VFA, with potential implications for optimising imaging strategies and glucocorticoid management.
- Open Access
- 19 December 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 227
Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis
Treatment of rheumatoid arthritis (RA) frequently requires Janus kinase inhibitors (JAKi) and biologic DMARDs (bDMARDs) with other mechanisms of action (OMA) after tumour necrosis factor inhibitors (TNFi) failure. Comparative safety data between JAKis and OMA in TNFi-inadequate responders (TNFi-IR) remain limited. To evaluate and compare safety profiles of JAKis versus OMA in TNFi-IR RA patients. A retrospective cohort study followed 305 RA patients (163 JAKis; 142 OMA) previously treated with TNFi for up to 24 months. Incidence rates (IR) of adverse events (AEs) per 100 patient-years (PY) and incidence rate ratios (IRR) adjusted for disease activity and previous bDMARD exposure were calculated using Poisson regression. At baseline, OMA patients had higher disease activity (DAS28-CRP = 4.5 vs. 3.8), whereas comorbidities and other baseline characteristics were similar. Overall, AE incidence was higher with OMA (IR 111.6/100 PY) compared to JAKis (IR 65.3/100 PY; adjusted IRR 1.67, 95% CI 1.22-2.31). Serious AEs occurred more frequently with OMA (IR 11.7/100 PY) versus JAKis (IR 7.9/100 PY; adjusted IRR 0.41, 95% CI 0.18-0.95). Infection rates were comparable; herpes zoster occurred exclusively in the JAKi group during the initial year. Venous thromboembolism, cardiovascular events, and malignancies were rare and similar between groups. In RA patients with inadequate response to TNFis, JAKis and OMA showed comparable safety profiles over 24 months. Serious AEs were numerically higher with OMA; herpes zoster was more frequent with JAKis. No new significant safety signals emerged.
- 19 December 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 227
Open AccessSafety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis
Treatment of rheumatoid arthritis (RA) frequently requires Janus kinase inhibitors (JAKi) and biologic DMARDs (bDMARDs) with other mechanisms of action (OMA) after tumour necrosis factor inhibitors (TNFi) failure. Comparative safety data between JAKis and OMA in TNFi-inadequate responders (TNFi-IR) remain limited. To evaluate and compare safety profiles of JAKis versus OMA in TNFi-IR RA patients. A retrospective cohort study followed 305 RA patients (163 JAKis; 142 OMA) previously treated with TNFi for up to 24 months. Incidence rates (IR) of adverse events (AEs) per 100 patient-years (PY) and incidence rate ratios (IRR) adjusted for disease activity and previous bDMARD exposure were calculated using Poisson regression. At baseline, OMA patients had higher disease activity (DAS28-CRP = 4.5 vs. 3.8), whereas comorbidities and other baseline characteristics were similar. Overall, AE incidence was higher with OMA (IR 111.6/100 PY) compared to JAKis (IR 65.3/100 PY; adjusted IRR 1.67, 95% CI 1.22-2.31). Serious AEs occurred more frequently with OMA (IR 11.7/100 PY) versus JAKis (IR 7.9/100 PY; adjusted IRR 0.41, 95% CI 0.18-0.95). Infection rates were comparable; herpes zoster occurred exclusively in the JAKi group during the initial year. Venous thromboembolism, cardiovascular events, and malignancies were rare and similar between groups. In RA patients with inadequate response to TNFis, JAKis and OMA showed comparable safety profiles over 24 months. Serious AEs were numerically higher with OMA; herpes zoster was more frequent with JAKis. No new significant safety signals emerged.
- Open Access
- 12 December 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS ( Vo closporin in R eal L ife S etting S tudy) experience
Objective: To assess efficacy of voclosporin (VCL) from a retrospective, observational, clinical-practice-based, nationwide multicentre study of patients with LN. Methods: Patients with biopsy-proven LN were enrolled from November 2023 to April 2025 from tertiary Rheumatology and Nephrology Italian Centres. Those with uncontrolled arterial hypertension and eGFR < 30 ml/min/1.73 m2 were excluded. Patients received oral 23.7 mg VCL BID and MMF 1 g BID. Glucocorticoid schedule followed existing recommendations for LN management. Clinical and serological data were collected at SLE diagnosis, VCL initiation and after 6, 12, 24 and 48 weeks. Complete renal response (CRR) was defined as eGFR ≥ 60 ml/min/1.73 m2, <20% eGFR decrease from baseline, 24-h proteinuria <0.5 g/day, no rescue therapy, prednisone ≤5 mg/day and partial renal response (PRR) as a 50% decrease of 24 h proteinuria and <20% eGFR decrease. Results: Forty-two patients from 14 centres were enrolled, 26 females (61.9%), mean age 43.1 ± 11.9 years, follow-up 6.6 ± 5.1 months. A total of 31.5% of patients achieved CRR or PRR at 6 weeks, 68.9% at 12 weeks, 83.3% at 24 weeks and 91.6% at 48 weeks of follow-up. A significant decrease in 24-h proteinuria was observed at 6 weeks (P = 0.006) and at all subsequent time points. A mild eGFR decrease was observed at 6 (P = 0.008) and 24 weeks (P = 0.01), but not at 48 weeks. Significant decrease was also observed in anti-dsDNA positivity at 6 (P = 0.0016) and 12 weeks (P = 0.0009), and in SLEDAI-2K after 24 (P = 0.008) and 48 weeks (P = 0.05). Conclusions: VCL may provide a valuable therapeutic option in LN management, achieving early 24 h-proteinuria response consistent with clinical trial data.
- 12 December 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Open AccessEarly antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS ( Vo closporin in R eal L ife S etting S tudy) experience
Objective: To assess efficacy of voclosporin (VCL) from a retrospective, observational, clinical-practice-based, nationwide multicentre study of patients with LN. Methods: Patients with biopsy-proven LN were enrolled from November 2023 to April 2025 from tertiary Rheumatology and Nephrology Italian Centres. Those with uncontrolled arterial hypertension and eGFR < 30 ml/min/1.73 m2 were excluded. Patients received oral 23.7 mg VCL BID and MMF 1 g BID. Glucocorticoid schedule followed existing recommendations for LN management. Clinical and serological data were collected at SLE diagnosis, VCL initiation and after 6, 12, 24 and 48 weeks. Complete renal response (CRR) was defined as eGFR ≥ 60 ml/min/1.73 m2, <20% eGFR decrease from baseline, 24-h proteinuria <0.5 g/day, no rescue therapy, prednisone ≤5 mg/day and partial renal response (PRR) as a 50% decrease of 24 h proteinuria and <20% eGFR decrease. Results: Forty-two patients from 14 centres were enrolled, 26 females (61.9%), mean age 43.1 ± 11.9 years, follow-up 6.6 ± 5.1 months. A total of 31.5% of patients achieved CRR or PRR at 6 weeks, 68.9% at 12 weeks, 83.3% at 24 weeks and 91.6% at 48 weeks of follow-up. A significant decrease in 24-h proteinuria was observed at 6 weeks (P = 0.006) and at all subsequent time points. A mild eGFR decrease was observed at 6 (P = 0.008) and 24 weeks (P = 0.01), but not at 48 weeks. Significant decrease was also observed in anti-dsDNA positivity at 6 (P = 0.0016) and 12 weeks (P = 0.0009), and in SLEDAI-2K after 24 (P = 0.008) and 48 weeks (P = 0.05). Conclusions: VCL may provide a valuable therapeutic option in LN management, achieving early 24 h-proteinuria response consistent with clinical trial data.
- Open Access
- 17 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in RA
Objectives: To evaluate the impact of oral low-dose glucocorticoids (GCs) on the effectiveness of Janus kinase inhibitors (JAKis) compared with non-TNF-targeted bDMARDs (other mechanisms of action [OMA] including tocilizumab, abatacept and rituximab) in RA patients with inadequate response to TNF inhibitors (TNFi-IRs). Methods: Single-centre, retrospective cohort study. The primary outcome was the good EULAR response at 6, 12 and 24 months. Secondary outcomes included treatment discontinuation and remission rates. Statistical analyses included structural equation modeling (SEM), competing risks analysis and linear mixed-effects models. Results: The study included 299 patients (JAKi = 161, OMA = 138). Baseline GC use was similar between the groups (JAKi = 66.5%, OMA = 76%; P = 0.089; mean (SD) daily dose 4.4 (5.5) vs 4.9 (4.5) mg/d; P = 0.355). The proportion of GC users treated with JAKi or OMA at 6, 12 and 24 months was 49.7% vs 63.8% (P = 0.036), 37.3% vs 40.6% (P = 0.161) and 27.3% vs 34.1% (P = 0.430). No statistically significant differences in GC dose reduction were observed between the two groups across any time interval. The EULAR response improved at 24 months, with JAKi outperforming OMA (SEM; P = 0.040). GC dosage at 6 months negatively affected the 24-month outcome (β = −0.456, P = 0.020). DAS28-CRP remission was more frequent in the JAKi group (P < 0.05), while discontinuation rates were similar (HR = 1.49, P = 0.34). Conclusion: JAKi did not show superiority over OMA regarding steroid-sparing effects; however, JAKi yielded higher remission rates. Exposure to GC at 6 months predicted poorer 24-month outcomes.
- 17 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessThe impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in RA
Objectives: To evaluate the impact of oral low-dose glucocorticoids (GCs) on the effectiveness of Janus kinase inhibitors (JAKis) compared with non-TNF-targeted bDMARDs (other mechanisms of action [OMA] including tocilizumab, abatacept and rituximab) in RA patients with inadequate response to TNF inhibitors (TNFi-IRs). Methods: Single-centre, retrospective cohort study. The primary outcome was the good EULAR response at 6, 12 and 24 months. Secondary outcomes included treatment discontinuation and remission rates. Statistical analyses included structural equation modeling (SEM), competing risks analysis and linear mixed-effects models. Results: The study included 299 patients (JAKi = 161, OMA = 138). Baseline GC use was similar between the groups (JAKi = 66.5%, OMA = 76%; P = 0.089; mean (SD) daily dose 4.4 (5.5) vs 4.9 (4.5) mg/d; P = 0.355). The proportion of GC users treated with JAKi or OMA at 6, 12 and 24 months was 49.7% vs 63.8% (P = 0.036), 37.3% vs 40.6% (P = 0.161) and 27.3% vs 34.1% (P = 0.430). No statistically significant differences in GC dose reduction were observed between the two groups across any time interval. The EULAR response improved at 24 months, with JAKi outperforming OMA (SEM; P = 0.040). GC dosage at 6 months negatively affected the 24-month outcome (β = −0.456, P = 0.020). DAS28-CRP remission was more frequent in the JAKi group (P < 0.05), while discontinuation rates were similar (HR = 1.49, P = 0.34). Conclusion: JAKi did not show superiority over OMA regarding steroid-sparing effects; however, JAKi yielded higher remission rates. Exposure to GC at 6 months predicted poorer 24-month outcomes.
- Open Access
- 1 September 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (10) , 1706-1718
Long-term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of Rheumatoid Arthritis Patients
- 1 September 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (10) , 1706-1718
Open AccessLong-term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of Rheumatoid Arthritis Patients
- Open Access
- 17 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4325-4330
Insights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS
Objectives: The 2023 American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) antiphospholipid syndrome (APS) classification criteria distinguish between anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) IgG vs IgM isotypes, having isolate IgM positivity a low weight, insufficient for APS classification, and define aCL and aβ2GPI thresholds based on fixed cut-off values. We aimed to assess the performance of the 2023 ACR/EULAR criteria in a cohort of primary vascular APS patients (PAPS), previously classified according to the Sydney criteria. Additionally, we evaluated the risk of thrombotic recurrence in patients re-classified or not according to the new criteria. Methods: PAPS patients meeting the Sydney criteria with previous vascular manifestations followed between 1992 and 2023 were re-evaluated to identify cases that would not be classified as PAPS based on the 2023 ACR/EULAR criteria. Results: Our cohort included 205 PAPS patients: 171 met the ACR/EULAR classification criteria, 34 (16.6%) did not due to insufficient score in the laboratory domain caused by isolate IgM positivity (23 patients) or aPL positivity at a titer >99th percentile but <40 units (11 patients). Notably, 9/34 (26%) patients not confirmed as PAPS had a thrombotic relapse during follow-up. The rate of thrombotic recurrence was similar between patients who fulfilled or not the new criteria. Conclusion: Among PAPS patients classified by Sydney criteria, 16.6% did not meet 2023 ACR/EULAR criteria. One quarter of them had a thrombotic relapse, confirming a pro-thrombotic profile. Inappropriately using these criteria as diagnostic in clinical practice could result in the lack of adequate antithrombotic therapy, exposing these patients to the risk of a new thrombotic event.
- 17 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4325-4330
Open AccessInsights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS
Objectives: The 2023 American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) antiphospholipid syndrome (APS) classification criteria distinguish between anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) IgG vs IgM isotypes, having isolate IgM positivity a low weight, insufficient for APS classification, and define aCL and aβ2GPI thresholds based on fixed cut-off values. We aimed to assess the performance of the 2023 ACR/EULAR criteria in a cohort of primary vascular APS patients (PAPS), previously classified according to the Sydney criteria. Additionally, we evaluated the risk of thrombotic recurrence in patients re-classified or not according to the new criteria. Methods: PAPS patients meeting the Sydney criteria with previous vascular manifestations followed between 1992 and 2023 were re-evaluated to identify cases that would not be classified as PAPS based on the 2023 ACR/EULAR criteria. Results: Our cohort included 205 PAPS patients: 171 met the ACR/EULAR classification criteria, 34 (16.6%) did not due to insufficient score in the laboratory domain caused by isolate IgM positivity (23 patients) or aPL positivity at a titer >99th percentile but <40 units (11 patients). Notably, 9/34 (26%) patients not confirmed as PAPS had a thrombotic relapse during follow-up. The rate of thrombotic recurrence was similar between patients who fulfilled or not the new criteria. Conclusion: Among PAPS patients classified by Sydney criteria, 16.6% did not meet 2023 ACR/EULAR criteria. One quarter of them had a thrombotic relapse, confirming a pro-thrombotic profile. Inappropriately using these criteria as diagnostic in clinical practice could result in the lack of adequate antithrombotic therapy, exposing these patients to the risk of a new thrombotic event.